These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22417933)

  • 1. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.
    Narasimhan S; Aquino TD; Multani PK; Rickels K; Lohoff FW
    Psychiatry Res; 2012 Jun; 198(1):112-5. PubMed ID: 22417933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.
    Lohoff FW; Aquino TD; Narasimhan S; Multani PK; Etemad B; Rickels K
    Pharmacogenomics J; 2013 Feb; 13(1):21-6. PubMed ID: 22006095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.
    Hopkins SC; Reasner DS; Koblan KS
    Psychiatry Res; 2013 Aug; 208(3):285-7. PubMed ID: 23706899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
    Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine XR in the treatment of anxiety.
    Hackett D
    Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder.
    Narasimhan S; Aquino TD; Hodge R; Rickels K; Lohoff FW
    Neurosci Lett; 2011 Oct; 503(3):200-2. PubMed ID: 21889574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder.
    Cooper AJ; Rickels K; Lohoff FW
    Hum Psychopharmacol; 2013 May; 28(3):258-62. PubMed ID: 23658070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of catechol-O-methyltransferase (COMT) rs4680 polymorphisms and generalized anxiety disorder in the Chinese Han population.
    He Q; Shen Z; Ren L; Wang X; Qian M; Zhu J; Shen X
    Int J Clin Exp Pathol; 2020; 13(7):1712-1719. PubMed ID: 32782694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.
    Chiesa A; Lia L; Alberti S; Lee SJ; Han C; Patkar AA; Pae CU; Serretti A
    Int J Psychiatry Clin Pract; 2014 Jun; 18(2):97-102. PubMed ID: 24555772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
    Taranu A; Asmar KE; Colle R; Ferreri F; Polosan M; David D; Becquemont L; Corruble E; Verstuyft C
    Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):435-441. PubMed ID: 28627776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence.
    Berrettini WH; Wileyto EP; Epstein L; Restine S; Hawk L; Shields P; Niaura R; Lerman C
    Biol Psychiatry; 2007 Jan; 61(1):111-8. PubMed ID: 16876132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study.
    Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Papageorgiou K; Linotte S; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
    Eur Neuropsychopharmacol; 2012 Apr; 22(4):259-66. PubMed ID: 21940152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder.
    Saung WT; Narasimhan S; Lohoff FW
    Hum Psychopharmacol; 2014 Jul; 29(4):316-21. PubMed ID: 24723432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.